Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.77 |
| ▸ | PPARA | Q07869 | 15/20 | 0.77 |
| ▸ | PPARD | Q03181 | 9/20 | 0.77 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5388062 | 1.00 | PPARG (0.77) | PPARGPPARAPPARDNR4A2RXRA | |
| SCHEMBL5377329 | 0.96 | PPARG (0.71) | PPARGPPARAPPARDNR4A2RXRA | |
| SCHEMBL5380210 | 0.87 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL5380219 | 0.87 | PPARG (1.00) | PPARGPPARAPPARD | |
| SCHEMBL27674846 | 0.87 | PPARA (0.84) | PPARGPPARAPPARD | |
| SCHEMBL5383887 | 0.87 | PPARA (0.84) | PPARGPPARAPPARD | |
| SCHEMBL5383883 | 0.87 | PPARA (0.84) | PPARGPPARAPPARD | |
| SCHEMBL5386010 | 0.86 | PPARG (0.83) | PPARGPPARAPPARD | |
| SCHEMBL5389900 | 0.86 | PPARG (0.83) | PPARGPPARAPPARD | |
| SCHEMBL6526812 | 0.85 | PPARG (0.73) | PPARGPPARAPPARDSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7192982-B2 | Modulators of peroxisome proliferator activated receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2007-03-20 | — | — | US | claimed |
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | ELI LILLY AND COMPANY | 2005-01-27 | — | — | US | claimed |
| EP-1392637-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | claimed |
| WO-2002100813-A2 | MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020684-A1 | Modulators of peroxisome proliferator activated receptors | NCOA4, PPARG, PPARA | PPARG 2/4885PPARA 3/4885PPARD 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.